Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Interstitial Lung Disease Market Between 2025 And 2029?
The interstitial lung disease market has seen significant growth in recent years. It is anticipated to increase from $1.97 billion in 2024 to $2.09 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.2%. This historical expansion can be attributed to enhancements in awareness and diagnosis, the advent of immune system modulation therapies, the establishment of respiratory rehabilitation programs, and the utilization of multidisciplinary care teams.
The interstitial lung disease market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.82 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.8%. Key drivers for this growth during the forecast period include precision medicine, the development of new drugs, regenerative medicine, and the adoption of telehealth and remote monitoring. Significant trends expected within this period encompass improvements in imaging technology, the application of AI in imaging, enhanced fibrosis subtype differentiation, and the provision of supportive care services.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13019&type=smp
Which Drivers Are Shaping The Interstitial Lung Disease Industry’s Market Share?
The increasing occurrence of allergic conditions is anticipated to drive the expansion of the interstitial lung disease market in the future. An allergic condition arises when the immune system responds excessively to an allergen, which is frequently an otherwise innocuous substance. Allergic reactions can manifest as interstitial lung disease (ILD), specifically hypersensitivity pneumonitis, a condition provoked by an allergic response in the body. For example, in November 2023, data from the National Asthma Council, an Australia-based non-profit organization dedicated to enhancing and managing asthma care in Australia, indicated 467 asthma-related fatalities in 2022, consisting of 299 females and 168 males. This number signifies a rise from the 355 deaths reported in 2021. The widespread occurrence of allergic diseases is fueling the expansion of the skin health foods market. Consequently, the increasing prevalence of allergic conditions is propelling the growth of the interstitial lung disease market.
What Are The Key Segments In The Interstitial Lung Disease Market?
The interstitial lung diseasemarket covered in this report is segmented –
1) By Drug Type: Oral Corticosteroids; Immune Suppressing; Anti-Fibrotic Medication; Other Drugs
2) By Disease Type: Interstitial Pneumonia; Idiopathic Pulmonary Fibrosis; Nonspecific Interstitial Pneumonitis; Hypersensitivity Pneumonitis; Cryptogenic Organizing Pneumonia (COP); Sarcoidosis; Acute Interstitial Pneumonitis
3) By Application: Adults; Children
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Oral Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
2) By Immune Suppressing: Azathioprine; Methotrexate; Mycophenolate Mofetil
3) By Anti-Fibrotic Medication: Pirfenidone; Nintedanib
4) By Other Drugs: Antioxidants; Anticoagulants; Other Novel Therapies
What Trends Are Expected To Drive The Interstitial Lung Disease Market?
Major companies in the interstitial lung disease market are concentrating on product launch trends, including advanced therapies for various interstitial lung conditions such as idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease marked by lung tissue scarring, which causes breathing difficulties and reduced oxygen transfer. For example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a Germany-based biopharmaceutical firm, obtained FDA approval for BI 1015550 Therapy to treat Idiopathic Pulmonary Fibrosis. BI 1015550 is an investigational oral treatment that inhibits phosphodiesterase 4B (PDE4B), providing antifibrotic and anti-inflammatory effects intended to slow the decline of lung function in idiopathic pulmonary fibrosis (IPF).
Who Are The Core Companies Influencing The Interstitial Lung Disease Market Landscape?
Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Interstitial Lung Disease Market?
North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Interstitial Lung Disease Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13019&type=smp
Browse Through More Reports Similar to the Global Interstitial Lung Disease Market 2025, By The Business Research Company
Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025
Respiratory Disposables Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Devices And Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model